NASDAQ:OCGN Ocugen (OCGN) Stock Price, News & Analysis $0.77 -0.05 (-6.62%) Closing price 04:00 PM EasternExtended Trading$0.77 0.00 (-0.26%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ocugen Stock (NASDAQ:OCGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ocugen alerts:Sign Up Key Stats Today's Range$0.74▼$0.8250-Day Range$0.70▼$1.3652-Week Range$0.69▼$2.73Volume9.04 million shsAverage Volume7.23 million shsMarket Capitalization$262.28 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingModerate Buy Company Overview Ocugen, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases and other eye conditions. Its approach includes modifier gene therapies designed to address multiple genetic causes of disease, rather than targeting a single mutation. The company’s clinical programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy associated with dry age-related macular degeneration, and OCU410ST for Stargardt disease. These programs are investigational and are not approved treatments. Ocugen has also pursued vaccine development. It previously partnered with Bharat Biotech to seek authorization for Covaxin, a COVID-19 vaccine, in the United States and Canada. The company is based in Malvern, Pennsylvania, and its development activities are primarily focused on the U.S. market.AI Generated. May Contain Errors. Read More Ocugen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreOCGN MarketRank™: 1.76213206046 of 5 starsOcugen scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingOcugen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOcugen has a consensus price target of $9.50, representing about 1,175.2% upside from its current price of $0.75.Amount of Analyst CoverageOcugen has only been the subject of 1 research reports in the past 90 days.Read more about Ocugen's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ocugen are expected to decrease in the coming year, from ($0.24) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocugen is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocugen is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted33.04% of the float of Ocugen has been sold short.Short Interest Ratio / Days to CoverOcugen has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.Change versus previous monthShort interest in Ocugen has recently increased by 0.48%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOcugen does not currently pay a dividend.Dividend GrowthOcugen does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.72 News SentimentOcugen has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Ocugen this week, compared to 6 articles on an average week.Search InterestOnly 10 people have searched for OCGN on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows7 people have added Ocugen to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ocugen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,088,801.00 in company stock.Percentage Held by Insiders3.95% of the stock of Ocugen is held by insiders.Percentage Held by Institutions10.27% of the stock of Ocugen is held by institutions.Read more about Ocugen's insider trading history. Receive OCGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCGN Stock News HeadlinesOcugen Stock Gets Stronger EPS Forecast from Noble FinancialNovember 15 at 10:32 AM | americanbankingnews.comOcugen Inc. stock rises Wednesday, still underperforms marketNovember 11, 2026 | marketwatch.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 16 at 1:00 AM | Base Camp Trading (Ad)Ocugen Signs Regional OCU400 Licensing Deal; Potential Payments Reach $7.1 MlnNovember 10, 2026 | rttnews.comOcugen inks licensing deal with Australia’s Celairis for gene therapyNovember 10, 2026 | msn.comOcugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEANNovember 10, 2026 | globenewswire.comH.C. Wainwright Remains a Buy on Ocugen (OCGN)November 8, 2026 | theglobeandmail.comHC Wainwright Issues Optimistic Estimate for Ocugen EarningsNovember 8, 2026 | americanbankingnews.comSee More Headlines OCGN Stock Analysis - Frequently Asked Questions How have OCGN shares performed this year? Ocugen's stock was trading at $1.35 at the beginning of the year. Since then, OCGN stock has decreased by 44.8% and is now trading at $0.7450. How were Ocugen's earnings last quarter? Ocugen, Inc. (NASDAQ:OCGN) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.02. The company had revenue of $1.49 million for the quarter, compared to analyst estimates of $889 thousand. Read the conference call transcript. When did Ocugen IPO? Ocugen (OCGN) raised $83 million in an initial public offering on Wednesday, December 3rd 2014. The company issued 5,909,091 shares at $13.00-$15.00 per share. Who are Ocugen's major shareholders? Top institutional investors of Ocugen include State Street Corp (5.76%), Marshall Wace LLP (0.49%), Profund Advisors LLC (0.05%) and Cora Capital Advisors LLC (0.03%). Insiders that own company stock include Shankar Musunuri, Treerita Essali Johnson-Greene and Prabhavathi Fernandes. View institutional ownership trends. How do I buy shares of Ocugen? Shares of OCGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ocugen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocugen investors own include NIO (NIO), Tesla (TSLA), AMC Entertainment (AMC), Palantir Technologies (PLTR), SNDL (SNDL), NVIDIA (NVDA) and Bionano Genomics (BNGO). Company Calendar Last Earnings8/06/2026Today11/16/2026AGM 202612/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 OCGN's financial health is in the Red zone, according to TradeSmith. OCGN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:OCGN CIK1372299 Webocugen.com Phone(484) 328-4701Fax781-547-4452Employees116Year Founded2013Price Target and Rating Average Price Target for Ocugen$9.50 High Price Target$11.00 Low Price Target$7.00 Potential Upside/Downside+1,129.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$67.85 million Net MarginsN/A Pretax Margin-1,367.61% Return on Equity-127,987.80% Return on Assets-98.50% Debt Debt-to-Equity Ratio4.17 Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$4.78 million Price / Sales54.87 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-19.33Miscellaneous Outstanding Shares339,307,000Free Float325,904,000Market Cap$262.28 million OptionableOptionable Beta2.04 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:OCGN) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.